Researchers at Colorado State University with Ray Goodrich are working on four COVID-19 vaccine candidates, one of which is nearing human clinical trials.
Ray Goodrich partners with Okoth to create an inactivated ASF vaccine that maintains the structure of the virus as close to the natural pathogen as possible.
A research team led by Ray Goodrich was awarded a $3.1 million base contract to continue development of a coronavirus vaccine candidate known as SolaVAX™.
Ray Goodrich develops the Mirasol Pathogen Reduction Technology System, a device which may help lower the possibility of COVID-19 transmission via blood transfusion.
Researchers led by Ray Goodrich focus on probiotics, ultraviolet light and vitamin B2 in developing vaccine candidates for coronavirus.
CSU engineering students and faculty use science from vaccine research led by Ray Goodrich to develop a disinfectant to kill coronavirus on surfaces.
Ray Goodrich and infectious disease researchers are moving quickly as they near key milestones in developing a vaccine for the new coronavirus.
MIP professor Ray Goodrich discusses CSU’s approach to researching a vaccine for coronavirus with CSU’s V.P for research and U.S. Sen. Michael Bennet.
Ray Goodrich has been awarded the Order of Military Medical Merit, recognizing him for his contributions to the U.S. Army Medical Department.